rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.14412/1995-4484-2019-496-510rsp-2782Research ArticleМЕЖДУНАРОДНЫЕ И РОССИЙСКИЕ РЕКОМЕНДАЦИИ ПО ЛЕЧЕНИЮ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЙINTERNATIONAL AND RUSSIAN GUIDELINES FOR THE TREATMENT OF RHEUMATIC DISEASESПо материалам обновленных рекомендаций Европейской антиревматической лиги (EULAR) по лечению системной красной волчанки – 2019: дискуссионные вопросы и комментарииAccording to the 2019 updated European League Against Rheumatism (EULAR) recommendations for the treatment of systemic lupus erythematosus: debatable issues and commentsПопковаТ. В.PopkovaT. V.

Попкова Татьяна Валентиновна.

115522, Москва, Каширское шоссе, 34А.

Tatiana Popkova.

34A, Kashirskoe Shosse, Moscow 115522.

popkovatv@mail.ruПанафидинаТ. А.PanafidinaT. A.

115522, Москва, Каширское шоссе, 34А.

34A, Kashirskoe Shosse, Moscow 115522.

СоловьевС. К.SolovyevS. K.

115522, Москва, Каширское шоссе, 34А.

34A, Kashirskoe Shosse, Moscow 115522.

Научно-исследовательский институт ревматологии им. В.А. НасоновойРоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation201914112019575496510Copyright © Попкова Т.В., Панафидина Т.А., Соловьев С.К., 20192019Попкова Т.В., Панафидина Т.А., Соловьев С.К.Popkova T.V., Panafidina T.A., Solovyev S.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2782

Многообразие клинических проявлений системной красной  волчанки  (СКВ),  волнообразное течение с чередованием ремиссий  и обострений  делают это заболевание одним из наиболее трудных для диагностики, лечения и оценки  эффективности терапии.

Несмотря  на то что разработанные в последние  годы методы ранней диагностики, способы применения комбинированной патогенетической терапии и мониторинга течения болезни привели  к увеличению  выживаемости (≥90%) и продолжительности жизни пациентов с СКВ, остается еще много нерешенных проблем. В частности, эффективность лечения СКВ пока не достаточна и полностью  контролировать активность  заболевания удается нечасто. Рецидивирующее течение СКВ в сочетании  с коморбидной патологией, а также неблагоприятным воздействием  глюкокортикоидов (ГК) и иммуносупрессантов способствует накоплению необратимых  органных повреждений.

Статья посвящена обзору обновленных рекомендаций Европейской антиревматической лиги (EULAR)  по лечению СКВ, которые были опубликованы в 2019 г. Представлены комментарии и дискуссионные вопросы с учетом российских  рекомендаций по лечению СКВ.

A diversity of the clinical manifestations of systemic lupus erythematosus (SLE) and its undulating course with alternating remissions and exacerbations make this disease one of the most difficult ones to diagnose, treat, and evaluate the efficiency of therapy.

Despite the fact that the recently developed methods for early diagnosis and procedures for combined pathogenetic therapy and monitoring  the disease course have led to increases in survival rates (≥90%) and life expectancy in patients with SLE, there are still many unsolved problems. In particular,  the treatment for SLE is not yet efficient enough and the activity of the latter cannot be completely controlled.  The relapsing and remitting course of SLE concurrent with comorbidity,  as well as the adverse effects of glucocorticoids  and immunosuppressants contribute to the accumulation of irreversible organ damages.

The paper is devoted to a review of the updated EULAR recommendations for the treatment of systemic lupus erythematosus, which were published in 2019. It presents comments  and debatable issues, by taking into account the Russian recommendations for the treatment of SLE.

системная красная волчанкалечениерекомендацииЕвропейская антиревматическая лига (EULAR)systemic lupus erythematosustreatmentrecommendationsEuropean League Against Rheumatism (EULAR)ReferencesНасонов ЕЛ, редактор. Клинические рекомендации по ревматологии. 2-е изд., испр. и доп. Москва: ГЭОТАР-Медиа; 2010. С. 429-8.Nasonov EL, editor. Klinicheskie rekomendatsii po revmatologii [Clinical recommendations for rheumatology]. 2nd ed. Moscow: GEOTAR-Media; 2010. P. 429-81 (In Russ.).Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61-4. doi: 10.1136/ard.2008.102533Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69:61-4. doi: 10.1136/ard.2008.102533Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139Van Vollenhoven RF, Mosca M, Bertsias G, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139Mosca M, Boumpas D, Bruce IN, et al. Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol. 2012;30(suppl.73): S112-115.Mosca M, Boumpas D, Bruce IN, et al. Treat-to-target in systemic lupus erythematosus: where are we today? Clin Exp Rheumatol. 2012;30(suppl.73): S112-115.Клюквина НГ. Алгоритм лечения системной красной волчанки. Современное состояние проблемы. Медицинский совет. 2016;(8):99-105 doi: 10.21518/2079-701X-2016-8Klyukvina NG. Algorithm for the treatment of systemic lupus erythematosus. The current state of the problem. Meditsinskiy Sovet. 2016;(8):99-105 (In Russ.). doi: 10.21518/2079-701X-2016-8Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task Force of the EULAR standing Committee for international clinical studies including therapeutics. Ann Rheum Dis. 2008;67(2):195-205. doi: 10.1136/ard.2007.070367Bertsias G, Ioannidis JPA, Boletis J, et al. EULAR recommendations for the management of systemic lupus erythematosus. Report of a task Force of the EULAR standing Committee for international clinical studies including therapeutics. Ann Rheum Dis. 2008;67(2):195-205. doi: 10.1136/ard.2007.070367Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task Force of the EULAR standing Committee for clinical Affairs. Ann Rheum Dis. 2010;69(12):2074-82. doi: 10.1136/ard.2010.130476Bertsias GK, Ioannidis JPA, Aringer M, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task Force of the EULAR standing Committee for clinical Affairs. Ann Rheum Dis. 2010;69(12):2074-82. doi: 10.1136/ard.2010.130476Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League against rheumatism and European Renal Association-European dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-82. doi: 10.1136/annrheumdis-2012-201940Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League against rheumatism and European Renal Association-European dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-82. doi: 10.1136/annrheumdis-2012-201940Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-85. doi: 10.1136/annrheumdis-2016-209770Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis. 2017;76(3):476-85. doi: 10.1136/annrheumdis-2016-209770Mosca M, Tani C, Aringer M, et al. European League against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-74. doi: 10.1136/ard.2009.117200Mosca M, Tani C, Aringer M, et al. European League against rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-74. doi: 10.1136/ard.2009.117200Boumpas DT, Bertsias GK, Fanouriakis A. 2008–2018: a decade of recommendations for systemic lupus erythematosus. Ann Rheum Dis. 2018;77(11):1547-8. doi: 10.1136/annrheumdis-2018-214014Boumpas DT, Bertsias GK, Fanouriakis A. 2008–2018: a decade of recommendations for systemic lupus erythematosus. Ann Rheum Dis. 2018;77(11):1547-8. doi: 10.1136/annrheumdis-2018-214014Попкова ТВ, Лисицына ТА. Рекомендации по ведению больных системной красной волчанкой в клинической практике (по материалам рекомендаций Европейской антиревматической лиги – EULAR). Современная ревматология. 2011;5(1):4-12 doi: 10.14412/1996-7012-2011-645Popkova TV, Lisitsyna TA. Recommendations for the management of patients with systemic lupus erythematosus in clinical practice (based on the recommendations of the European Anti-Rheumatic League – EULAR). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2011;5(1):4-12 (In Russ.). doi: 10.14412/1996-7012-2011-645Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45. doi: 10.1136/annrheumdis-2019-215089Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45. doi: 10.1136/annrheumdis-2019-215089Van der Heijde D, Aletaha D, Carmona L. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74(1):8-13. doi: 10.1136/annrheumdis-2014-206350Van der Heijde D, Aletaha D, Carmona L. 2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. Ann Rheum Dis. 2015;74(1):8-13. doi: 10.1136/annrheumdis-2014-206350Van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international Task Force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76(3):554-61. doi: 10.1136/annrheumdis-2016-209519Van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international Task Force on definitions of remission in SLE (DORIS). Ann Rheum Dis. 2017;76(3):554-61. doi: 10.1136/annrheumdis-2016-209519Соловьев СК, Асеева ЕА, Попкова ТВ и др. Стратегия лечения системной красной волчанки «до достижения цели» (Treat-to-Target SLE). Рекомендации международной рабочей группы и комментарии российских экспертов. Научно-практическая ревматология. 2015;53(1):9-16 doi: 10.14412/1995-4484-2015-9-16Soloviev SK, Aseeva EA, Popkova TV, et al. Treat-to-target SLE recommendations from the International Task Force and Russian experts’ commentaries. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2015;53(1):9-16 (In Russ.). doi: 10.14412/1995-4484-2015-9-16Medina-Quinones CV, Ramos-Merino L, Ruiz-Sada P, et al. Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken). 2016;68(7):981-7. doi: 10.1002/acr.22774Medina-Quinones CV, Ramos-Merino L, Ruiz-Sada P, et al. Analysis of complete remission in systemic lupus erythematosus patients over a 32-year period. Arthritis Care Res (Hoboken). 2016;68(7):981-7. doi: 10.1002/acr.22774Steiman AJ, Urowitz MB, Ibanez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(9):1808-16. doi: 10.3899/jrheum.131137Steiman AJ, Urowitz MB, Ibanez D, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol. 2014;41(9):1808-16. doi: 10.3899/jrheum.131137Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, et al. Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). Ann Rheum Dis. 2017;76(12):2071-4. doi: 10.1136/annrheumdis-2017-211814Ugarte-Gil MF, Wojdyla D, Pons-Estel GJ, et al. Remission and low disease activity status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American lupus cohort (GLADEL). Ann Rheum Dis. 2017;76(12):2071-4. doi: 10.1136/annrheumdis-2017-211814Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32:1467-72.Urowitz MB, Feletar M, Bruce IN, et al. Prolonged remission in systemic lupus erythematosus. J Rheumatol 2005; 32:1467-72.Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis. 2015;74(12):2117-22. doi: 10.1136/annrheumdis-2015-207347Zen M, Iaccarino L, Gatto M, et al. Prolonged remission in Caucasian patients with SLE: prevalence and outcomes. Ann Rheum Dis. 2015;74(12):2117-22. doi: 10.1136/annrheumdis-2015-207347Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, et al. Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(1):121-8. doi: 10.1093/rheumatology/kew377Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, et al. Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford). 2017;56(1):121-8. doi: 10.1093/rheumatology/kew377Zen M, Iaccarino L, Gatto M, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis. 2018;77(1):104-10. doi: 10.1136/annrheumdis-2017-211613Zen M, Iaccarino L, Gatto M, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis. 2018;77(1):104-10. doi: 10.1136/annrheumdis-2017-211613Polachek A, Gladman DD, Su J, et al. Defining low disease activity in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69(7):997-1003. doi: 10.1002/acr.23109Polachek A, Gladman DD, Su J, et al. Defining low disease activity in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2017;69(7):997-1003. doi: 10.1002/acr.23109Tselios K, Gladman DD, Touma Z, et al. Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2019;71(6):822-8. doi: 10.1002/acr.23720Tselios K, Gladman DD, Touma Z, et al. Clinical remission and low disease activity have comparable outcomes over 10 years in systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2019;71(6):822-8. doi: 10.1002/acr.23720Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of longterm renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort. Arthritis Rheum. 2015;67(5):1305-13. doi: 10.1002/art.39026Dall'Era M, Cisternas MG, Smilek DE, et al. Predictors of longterm renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort. Arthritis Rheum. 2015;67(5):1305-13. doi: 10.1002/art.39026Touma Z, Urowitz MB, Ibanez D, et al. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol. 2014;41(4):688-97. doi: 10.3899/jrheum.130005Touma Z, Urowitz MB, Ibanez D, et al. Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment. J Rheumatol. 2014;41(4):688-97. doi: 10.3899/jrheum.130005Mackay M, Dall'Era M, Fishbein J, et al. Establishing surrogate kidney endpoints for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheum. 2019;71(3):411-9. doi: 10.1002/art.40724Mackay M, Dall'Era M, Fishbein J, et al. Establishing surrogate kidney endpoints for lupus nephritis clinical trials: development and validation of a novel approach to predict future kidney outcomes. Arthritis Rheum. 2019;71(3):411-9. doi: 10.1002/art.40724Ruperto N, Hanrahan LM, Alarcon GS, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011;20(5):453-62. doi: 10.1177/0961203310388445Ruperto N, Hanrahan LM, Alarcon GS, et al. International consensus for a definition of disease flare in lupus. Lupus. 2011;20(5):453-62. doi: 10.1177/0961203310388445Koutsonikoli A, Trachana M, Heidich A-B, et al. Dissecting the damage in northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study. Rheumatol Int. 2015;35(7):1225-32. doi: 10.1007/s00296-014-3209-6Koutsonikoli A, Trachana M, Heidich A-B, et al. Dissecting the damage in northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study. Rheumatol Int. 2015;35(7):1225-32. doi: 10.1007/s00296-014-3209-6Ugarte-Gil MF, Acevedo-Vasquez E, Alarcon GS, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis. 2015;74(6):1019-23. doi: 10.1136/annrheumdis-2013-204620Ugarte-Gil MF, Acevedo-Vasquez E, Alarcon GS, et al. The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Ann Rheum Dis. 2015;74(6):1019-23. doi: 10.1136/annrheumdis-2013-204620Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis. 2016;75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis. 2016;75(9):1615-21. doi: 10.1136/annrheumdis-2015-207726Kasitanon N, Intaniwet T, Wangkaew S, et al. The clinically quiescent phase in early diagnosed SLE patients: inception cohort study. Rheumatology. 2015;54(5):868-75. doi: 10.1093/rheumatology/keu406Kasitanon N, Intaniwet T, Wangkaew S, et al. The clinically quiescent phase in early diagnosed SLE patients: inception cohort study. Rheumatology. 2015;54(5):868-75. doi: 10.1093/rheumatology/keu406Steiman AJ, Gladman DD, Ibanez D, et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken). 2012;64(4):511-8. doi: 10.1002/acr.21568Steiman AJ, Gladman DD, Ibanez D, et al. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken). 2012;64(4):511-8. doi: 10.1002/acr.21568Соловьев СК, Асеева ЕА, Зоткин ЕГ и др. Проблемы низкой активности и ремиссии при системной красной волчанке. Научно-практическая ревматология. 2019;57(2):218-21 doi: 10.14412/1995-4484-2019-218-221Soloviev SK, Aseeva EA, Zotkin EG, et al. Problems of low activity and remission in systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(2):218-21 (In Russ.). doi: 10.14412/1995-4484-2019-218-221Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-8. doi: 10.1136/ard.2008.101766Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis. 2010;69(1):20-8. doi: 10.1136/ard.2008.101766Costedoat-Chalumeau N, Amoura Z, Hulot J-S, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821-4. doi: 10.1136/ard.2006.067835Costedoat-Chalumeau N, Amoura Z, Hulot J-S, et al. Very low blood hydroxychloroquine concentration as an objective marker of poor adherence to treatment of systemic lupus erythematosus. Ann Rheum Dis. 2007;66:821-4. doi: 10.1136/ard.2006.067835Iudici M, Pantano I, Fasano S, et al. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. Lupus. 2018;27(2):265-72. doi: 10.1177/0961203317717631Iudici M, Pantano I, Fasano S, et al. Health status and concomitant prescription of immunosuppressants are risk factors for hydroxychloroquine non-adherence in systemic lupus patients with prolonged inactive disease. Lupus. 2018;27(2):265-72. doi: 10.1177/0961203317717631Mok CC, Penn HJ, Chan KL, et al. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res (Hoboken). 2016;68(9):1295-302. doi: 10.1002/acr.22837Mok CC, Penn HJ, Chan KL, et al. Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis. Arthritis Care Res (Hoboken). 2016;68(9):1295-302. doi: 10.1002/acr.22837Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453-60. doi: 10.1001/jamaophthalmol.2014.3459Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132(12):1453-60. doi: 10.1001/jamaophthalmol.2014.3459Kim J-W, Kim YY, Lee H, et al. Risk of retinal toxicity in longterm users of hydroxychloroquine. J Rheumatol. 2017;44(11):1674-9. doi: 10.3899/jrheum.170158Kim J-W, Kim YY, Lee H, et al. Risk of retinal toxicity in longterm users of hydroxychloroquine. J Rheumatol. 2017;44(11):1674-9. doi: 10.3899/jrheum.170158Food and Drug Administration. Guidance for Industry-Systemic Lupus Erythematosus-Developing Medical Products for Treatment. Available from: http://google2.fda.gov/search?q=lupus+trials&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&requiredfields=-archive:Yes&output=xml_no_dtd&getfields=* (accessed 10 March 2014).Food and Drug Administration. Guidance for Industry-Systemic Lupus Erythematosus-Developing Medical Products for Treatment. Available from: http://google2.fda.gov/search?q=lupus+trials&client=FDAgov&site=FDAgov&lr=&proxystylesheet=FDAgov&requiredfields=-archive:Yes&output=xml_no_dtd&getfields=* (accessed 10 March 2014).Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, et al. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol. 2018;45(10):1426-39. doi: 10.3899/jrheum.171459Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, et al. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol. 2018;45(10):1426-39. doi: 10.3899/jrheum.171459Bruce IN, O'Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis. 2015;74(9):1706-13. doi: 10.1136/annrheumdis-2013-205171Bruce IN, O'Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis. 2015;74(9):1706-13. doi: 10.1136/annrheumdis-2013-205171Chen H-L, Shen L-J, Hsu P-N, et al. Cumulative burden of Glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol. 2018;45(1):83-89. doi: 10.3899/jrheum.160214Chen H-L, Shen L-J, Hsu P-N, et al. Cumulative burden of Glucocorticoid-related adverse events in patients with systemic lupus erythematosus: findings from a 12-year longitudinal study. J Rheumatol. 2018;45(1):83-89. doi: 10.3899/jrheum.160214Lim LSH, Pullenayegum E, Lim L, et al. From childhood to adulthood: the trajectory of damage in patients with juvenileonset systemic lupus erythematosus. Arthritis Care Res. (Hoboken). 2017;69(11):1627-35. doi: 10.1002/acr.23199Lim LSH, Pullenayegum E, Lim L, et al. From childhood to adulthood: the trajectory of damage in patients with juvenileonset systemic lupus erythematosus. Arthritis Care Res. (Hoboken). 2017;69(11):1627-35. doi: 10.1002/acr.23199Yee C-S, Su L, Toescu V, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford). 2015;54(5):836-43. doi: 10.1093/rheumatology/keu412Yee C-S, Su L, Toescu V, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years. Rheumatology (Oxford). 2015;54(5):836-43. doi: 10.1093/rheumatology/keu412Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus – the Hopkins Lupus Cohort. Lupus Sci Med. 2015 Mar;2(1):e000066. doi: 10.1136/lupus-2014-000066. eCollection 2015.Al Sawah S, Zhang X, Zhu B, et al. Effect of corticosteroid use by dose on the risk of developing organ damage over time in systemic lupus erythematosus – the Hopkins Lupus Cohort. Lupus Sci Med. 2015 Mar;2(1):e000066. doi: 10.1136/lupus-2014-000066. eCollection 2015.Ruiz-Arruza I, Barbosa C, Ugarte A, et al. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015;14(10):875-9. doi: 10.1016/j.autrev.2015.05.011Ruiz-Arruza I, Barbosa C, Ugarte A, et al. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. Autoimmun Rev. 2015;14(10):875-9. doi: 10.1016/j.autrev.2015.05.011Thamer MAE, Hernan MA, Zhang YI, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009;36(3):560-4. doi: 10.3899/jrheum.080828Thamer MAE, Hernan MA, Zhang YI, et al. Prednisone, lupus activity, and permanent organ damage. J Rheumatol. 2009;36(3):560-4. doi: 10.3899/jrheum.080828Buttgereit F, da Silva JAP, Boers M, et al. Standardised Nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718-22. doi: 10.1136/ard.61.8.718Buttgereit F, da Silva JAP, Boers M, et al. Standardised Nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718-22. doi: 10.1136/ard.61.8.718Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res (Hoboken). 2018;70(4):582-91. doi: 10.1002/acr.23322Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, et al. Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res (Hoboken). 2018;70(4):582-91. doi: 10.1002/acr.23322Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, et al. Repeated pulses of methylprednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16(8):826-32. doi: 10.1016/j.autrev.2017.05.017Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, et al. Repeated pulses of methylprednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16(8):826-32. doi: 10.1016/j.autrev.2017.05.017Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012;51(7):1145-53. doi: 10.1093/rheumatology/ker410Ruiz-Irastorza G, Danza A, Khamashta M. Glucocorticoid use and abuse in SLE. Rheumatology (Oxford). 2012;51(7):1145-53. doi: 10.1093/rheumatology/ker410Pego-Reigosa JM, Cobo-Ibanez T, Calvo-Alen J, et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2013;65(11):1775-85. doi: 10.1002/acr.22035Pego-Reigosa JM, Cobo-Ibanez T, Calvo-Alen J, et al. Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review. Arthritis Care Res (Hoboken). 2013;65(11):1775-85. doi: 10.1002/acr.22035Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014; 23:225-35.Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy. Lupus. 2014; 23:225-35.Tselios K, Gladman DD, Su J, et al. Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. J Rheumatol. 2016;43(3):552-8. doi: 10.3899/jrheum.150779Tselios K, Gladman DD, Su J, et al. Mycophenolate mofetil in nonrenal manifestations of systemic lupus erythematosus: an observational cohort study. J Rheumatol. 2016;43(3):552-8. doi: 10.3899/jrheum.150779Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69-78. doi: 10.3899/jrheum.100130Touma Z, Gladman DD, Urowitz MB, et al. Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis. J Rheumatol. 2011;38(1):69-78. doi: 10.3899/jrheum.100130Ordi-Ros J, Saez-Comet L, Perez-Conesa M, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017;76(9):1575-82. doi: 10.1136/annrheumdis-2016-210882Ordi-Ros J, Saez-Comet L, Perez-Conesa M, et al. Enteric-coated mycophenolate sodium versus azathioprine in patients with active systemic lupus erythematosus: a randomised clinical trial. Ann Rheum Dis. 2017;76(9):1575-82. doi: 10.1136/annrheumdis-2016-210882Knight JH, Howards PP, Spencer JB, et al. Characteristics related to early secondary amenorrhoea and pregnancy among women diagnosed with systemic lupus erythematosus: an analysis using the goal study. Lupus Sci Med. 2016;3(1):e000139. Collection 2016.Knight JH, Howards PP, Spencer JB, et al. Characteristics related to early secondary amenorrhoea and pregnancy among women diagnosed with systemic lupus erythematosus: an analysis using the goal study. Lupus Sci Med. 2016;3(1):e000139. Collection 2016.Mok CC, Chan PT, To CH. Anti-Mü llerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013;65(1):206-10. doi: 10.1002/art.37719Mok CC, Chan PT, To CH. Anti-Mü llerian hormone and ovarian reserve in systemic lupus erythematosus. Arthritis Rheum. 2013;65(1):206-10. doi: 10.1002/art.37719Tamirou F, Husson SN, Gruson D, et al. Brief report: The Euro-Lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of antimü llerian hormone. Arthritis Rheum. 2017;69(6):1267-71. doi: 10.1002/art.40079Tamirou F, Husson SN, Gruson D, et al. Brief report: The Euro-Lupus low-dose intravenous cyclophosphamide regimen does not impact the ovarian reserve, as measured by serum levels of antimü llerian hormone. Arthritis Rheum. 2017;69(6):1267-71. doi: 10.1002/art.40079Blumenfeld Z, Mischari O, Schultz N, et al. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Semin Arthritis Rheum. 2011;41(3):346-52. doi: 10.1016/j.semarthrit.2011.05.008Blumenfeld Z, Mischari O, Schultz N, et al. Gonadotropin releasing hormone agonists may minimize cyclophosphamide associated gonadotoxicity in SLE and autoimmune diseases. Semin Arthritis Rheum. 2011;41(3):346-52. doi: 10.1016/j.semarthrit.2011.05.008Marder W, McCune WJ, Wang L, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28(8):624-7. doi: 10.3109/09513590.2011.650752Marder W, McCune WJ, Wang L, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol Endocrinol. 2012;28(8):624-7. doi: 10.3109/09513590.2011.650752Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138-42. doi: 10.1136/annrheumdis-2012-202099Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann Rheum Dis. 2014;73(1):138-42. doi: 10.1136/annrheumdis-2012-202099Hsu CY, Lin MS, Su YJ, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2017;56(4):620-8. doi: 10.1093/rheumatology/kew457Hsu CY, Lin MS, Su YJ, et al. Cumulative immunosuppressant exposure is associated with diversified cancer risk among 14 832 patients with systemic lupus erythematosus: a nested case-control study. Rheumatology (Oxford). 2017;56(4):620-8. doi: 10.1093/rheumatology/kew457Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44(2):175-85. doi: 10.1016/j.semarthrit.2014.04.002Cobo-Ibanez T, Loza-Santamaria E, Pego-Reigosa JM, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44(2):175-85. doi: 10.1016/j.semarthrit.2014.04.002Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215-26. doi: 10.1002/art.34359Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus nephritis assessment with rituximab study. Arthritis Rheum. 2012;64(4):1215-26. doi: 10.1002/art.34359Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-30. doi: 10.1002/art.30613Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63(12):3918-30. doi: 10.1002/art.30613Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebocontrolled, phase 3 trial. Lancet. 2011;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebocontrolled, phase 3 trial. Lancet. 2011;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2Iaccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018; 86:1-8. doi: 10.1016/j.jaut.2017.09.004Iaccarino L, Andreoli L, Bocci EB, et al. Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric, nationwide study. J Autoimmun. 2018; 86:1-8. doi: 10.1016/j.jaut.2017.09.004Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-8. doi: 10.1136/annrheumdis-2011-200831Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833-8. doi: 10.1136/annrheumdis-2011-200831Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937Van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357-64. doi: 10.1016/j.autrev.2011.10.009Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev. 2012;11(5):357-64. doi: 10.1016/j.autrev.2011.10.009Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and metaanalysis. Lupus. 2013;22(14):1489-503. doi: 10.1177/0961203313509295Duxbury B, Combescure C, Chizzolini C. Rituximab in systemic lupus erythematosus: an updated systematic review and metaanalysis. Lupus. 2013;22(14):1489-503. doi: 10.1177/0961203313509295Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of offlabel use of rituximab in refractory lupus: data from the Italian multicentre registry. Clin Exp Rheumatol. 2015;33(4):449-56.Iaccarino L, Bartoloni E, Carli L, et al. Efficacy and safety of offlabel use of rituximab in refractory lupus: data from the Italian multicentre registry. Clin Exp Rheumatol. 2015;33(4):449-56.Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases. Lupus. 2009;18(9):767-76. doi: 10.1177/0961203309106174Ramos-Casals M, Soto MJ, Cuadrado MJ, et al. Rituximab in systemic lupus erythematosusA systematic review of off-label use in 188 cases. Lupus. 2009;18(9):767-76. doi: 10.1177/0961203309106174Olfat M, Silverman ED, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus. 2015;24(9):966-72. doi: 10.1177/0961203315578764Olfat M, Silverman ED, Levy DM. Rituximab therapy has a rapid and durable response for refractory cytopenia in childhood-onset systemic lupus erythematosus. Lupus. 2015;24(9):966-72. doi: 10.1177/0961203315578764Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(8):2458-66. doi: 10.1002/art.27541Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry. Arthritis Rheum. 2010;62(8):2458-66. doi: 10.1002/art.27541Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and metaanalysis. Lancet Haematol. 2015;2(2):75-81. doi: 10.1016/S2352-3026(15)00003-4Chugh S, Darvish-Kazem S, Lim W, et al. Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and metaanalysis. Lancet Haematol. 2015;2(2):75-81. doi: 10.1016/S2352-3026(15)00003-4Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant. 2009;24(7):2157-60. doi: 10.1093/ndt/gfp002Boletis JN, Marinaki S, Skalioti C, et al. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant. 2009;24(7):2157-60. doi: 10.1093/ndt/gfp002Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-9. doi: 10.2215/CJN.01070118Gomez Mendez LM, Cascino MD, Garg J, et al. Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol. 2018;13(10):1502-9. doi: 10.2215/CJN.01070118Kuhn A, Aberer E, Bata-Csö rgö Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017;31(3):389-404. doi: 10.1111/jdv.14053Kuhn A, Aberer E, Bata-Csö rgö Z, et al. S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol. 2017;31(3):389-404. doi: 10.1111/jdv.14053Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000; 42:983-7.Jewell ML, McCauliffe DP. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment. J Am Acad Dermatol. 2000; 42:983-7.Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: A randomized, vehicle-controlled, doubleblind study. J Am Acad Dermatol. 2011;64(1):37-48. doi: 10.1016/j.jaad.2009.12.053Kuhn A, Gensch K, Haust M, et al. Photoprotective effects of a broad-spectrum sunscreen in ultraviolet-induced cutaneous lupus erythematosus: A randomized, vehicle-controlled, doubleblind study. J Am Acad Dermatol. 2011;64(1):37-48. doi: 10.1016/j.jaad.2009.12.053Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol. 2004;51(3):407-10. doi: 10.1016/j.jaad.2004.01.044Kreuter A, Gambichler T, Breuckmann F, et al. Pimecrolimus 1% cream for cutaneous lupus erythematosus. J Am Acad Dermatol. 2004;51(3):407-10. doi: 10.1016/j.jaad.2004.01.044Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011;65(1):54-64,64.e1-2. doi: 10.1016/j.jaad.2010.03.037Kuhn A, Gensch K, Haust M, et al. Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: A multicenter, randomized, double-blind, vehicle-controlled trial. J Am Acad Dermatol. 2011;65(1):54-64,64.e1-2. doi: 10.1016/j.jaad.2010.03.037Costedoat-Chalumeau N, Dunogue B, Leroux G, et al. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol. 2015;49(3):317-26. doi: 10.1007/s12016-015-8469-8Costedoat-Chalumeau N, Dunogue B, Leroux G, et al. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. Clin Rev Allergy Immunol. 2015;49(3):317-26. doi: 10.1007/s12016-015-8469-8Chasset F, Arnaud L, Jachiet M, et al. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study. J Am Acad Dermatol. 2018;78(1):107-14.e1. doi: 10.1016/j.jaad.2017.08.045Chasset F, Arnaud L, Jachiet M, et al. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: a multicenter observational study. J Am Acad Dermatol. 2018;78(1):107-14.e1. doi: 10.1016/j.jaad.2017.08.045Chasset F, Bouaziz J-D, Costedoat-Chalumeau N, et al. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol. 2017;177(1):188-96. doi: 10.1111/bjd.15312Chasset F, Bouaziz J-D, Costedoat-Chalumeau N, et al. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis. Br J Dermatol. 2017;177(1):188-96. doi: 10.1111/bjd.15312Cavazzana I, Sala R, Bazzani C, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus. 2009;18(8):735-9. doi: 10.1177/0961203308101714Cavazzana I, Sala R, Bazzani C, et al. Treatment of lupus skin involvement with quinacrine and hydroxychloroquine. Lupus. 2009;18(8):735-9. doi: 10.1177/0961203308101714Fruchter R, Kurtzman DJB, Patel M, et al. Characteristics and alternative treatment outcomes of antimalarial-refractory cutaneous lupus erythematosus. JAMA Dermatol. 2017;153(9):937-9. doi: 10.1001/jamadermatol.2017.1160Fruchter R, Kurtzman DJB, Patel M, et al. Characteristics and alternative treatment outcomes of antimalarial-refractory cutaneous lupus erythematosus. JAMA Dermatol. 2017;153(9):937-9. doi: 10.1001/jamadermatol.2017.1160Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarialresistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;65(4):717-21. e2. doi: 10.1016/j.jaad.2010.08.011Gammon B, Hansen C, Costner MI. Efficacy of mycophenolate mofetil in antimalarialresistant cutaneous lupus erythematosus. J Am Acad Dermatol. 2011;65(4):717-21. e2. doi: 10.1016/j.jaad.2010.08.011Kreuter A, Tomi NS, Weiner SM, et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007;156(6):1321-7. doi: 10.1111/j.1365-2133.2007. 07826.xKreuter A, Tomi NS, Weiner SM, et al. Mycophenolate sodium for subacute cutaneous lupus erythematosus resistant to standard therapy. Br J Dermatol. 2007;156(6):1321-7. doi: 10.1111/j.1365-2133.2007. 07826.xMd Yusof MY, Shaw D, El-Sherbiny YM, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76(11):1829-36. doi: 10.1136/annrheumdis-2017-211191Md Yusof MY, Shaw D, El-Sherbiny YM, et al. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus. Ann Rheum Dis. 2017;76(11):1829-36. doi: 10.1136/annrheumdis-2017-211191Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheum. 2015;67(6):1586-91. doi: 10.1002/art.39085Vital EM, Wittmann M, Edward S, et al. Brief report: responses to rituximab suggest B cell-independent inflammation in cutaneous systemic lupus erythematosus. Arthritis Rheum. 2015;67(6):1586-91. doi: 10.1002/art.39085Chasset F, Tounsi T, Cesbron E, et al. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;78(2):342-350.e4. doi: 10.1016/j.jaad.2017.09.059Chasset F, Tounsi T, Cesbron E, et al. Efficacy and tolerance profile of thalidomide in cutaneous lupus erythematosus: a systematic review and meta-analysis. J Am Acad Dermatol. 2018;78(2):342-350.e4. doi: 10.1016/j.jaad.2017.09.059Cortes-Hernandez J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. 2012;166(3):616-23. doi: 10.1111/j.1365-2133.2011. 10693.xCortes-Hernandez J, Torres-Salido M, Castro-Marrero J, et al. Thalidomide in the treatment of refractory cutaneous lupus erythematosus: prognostic factors of clinical outcome. Br J Dermatol. 2012;166(3):616-23. doi: 10.1111/j.1365-2133.2011. 10693.xBortoluzzi A, Scire CA, Bombardieri S, et al. Development and validation of a new algorithm for Attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54(5):891-8. doi: 10.1093/rheumatology/keu384Bortoluzzi A, Scire CA, Bombardieri S, et al. Development and validation of a new algorithm for Attribution of neuropsychiatric events in systemic lupus erythematosus. Rheumatology (Oxford). 2015;54(5):891-8. doi: 10.1093/rheumatology/keu384The American College of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999; 42:599-608. doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-FThe American College of rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999; 42:599-608. doi: 10.1002/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-FBortoluzzi A, Fanouriakis A, Appenzeller S, et al. Validity of the Italian algorithm for the Attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective multicentre international diagnostic cohort study. BMJ Open. 2017;7(5): e015546. doi: 10.1136/bmjopen-2016-015546Bortoluzzi A, Fanouriakis A, Appenzeller S, et al. Validity of the Italian algorithm for the Attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective multicentre international diagnostic cohort study. BMJ Open. 2017;7(5): e015546. doi: 10.1136/bmjopen-2016-015546Magro-Checa C, Zirkzee EJ, Beaart-van de Voorde LJJ, et al. Value of multidisciplinary reassessment in Attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from The Leiden NPSLE cohort. Rheumatology (Oxford). 2017;56(10):1676-83. doi: 10.1093/rheumatology/kex019Magro-Checa C, Zirkzee EJ, Beaart-van de Voorde LJJ, et al. Value of multidisciplinary reassessment in Attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from The Leiden NPSLE cohort. Rheumatology (Oxford). 2017;56(10):1676-83. doi: 10.1093/rheumatology/kex019Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010;6(6):358-67. doi: 10.1038/nrrheum.2010.62Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol. 2010;6(6):358-67. doi: 10.1038/nrrheum.2010.62Bortoluzzi A, Padovan M, Farina I, et al. Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre. Reumatismo. 2012;64(6):350-9. doi: 10.4081/reumatismo.2012.350Bortoluzzi A, Padovan M, Farina I, et al. Therapeutic strategies in severe neuropsychiatric systemic lupus erythematosus: experience from a tertiary referral centre. Reumatismo. 2012;64(6):350-9. doi: 10.4081/reumatismo.2012.350Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142-50. doi: 10.1212/WNL.0000000000000570Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83(2):142-50. doi: 10.1212/WNL.0000000000000570Fanouriakis A, Pamfil C, Sidiropoulos P, et al. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus. 2016;25(6):627-36. doi: 10.1177/0961203315622821Fanouriakis A, Pamfil C, Sidiropoulos P, et al. Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. Lupus. 2016;25(6):627-36. doi: 10.1177/0961203315622821Gupta N, Ganpati A, Mandal S, et al. Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India. Clin Rheumatol. 2017;36(10):2273-9. doi: 10.1007/s10067-017-3775-6Gupta N, Ganpati A, Mandal S, et al. Mycophenolate mofetil and deflazacort combination in neuropsychiatric lupus: a decade of experience from a tertiary care teaching hospital in southern India. Clin Rheumatol. 2017;36(10):2273-9. doi: 10.1007/s10067-017-3775-6Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41(3):364-72. doi: 10.1016/j.semarthrit.2011.06.004Narvaez J, Rios-Rodriguez V, de la Fuente D, et al. Rituximab therapy in refractory neuropsychiatric lupus: current clinical evidence. Semin Arthritis Rheum. 2011;41(3):364-72. doi: 10.1016/j.semarthrit.2011.06.004Pamfil C, Fanouriakis A, Damian L, et al. EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheumatology (Oxford). 2015 Jul;54(7):1270-8. doi: 10.1093/rheumatology/keu482. Epub 2015 Jan 30.Pamfil C, Fanouriakis A, Damian L, et al. EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. Rheumatology (Oxford). 2015 Jul;54(7):1270-8. doi: 10.1093/rheumatology/keu482. Epub 2015 Jan 30.Jung J-H, Soh M-S, Ahn Y-H, et al. Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine (Baltimore). 2016;95(6): e2818. doi: 10.1097/MD.0000000000002818Jung J-H, Soh M-S, Ahn Y-H, et al. Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients. Medicine (Baltimore). 2016;95(6): e2818. doi: 10.1097/MD.0000000000002818Serris A, Amoura Z, Canoui-Poitrine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol. 2018;93(3):424-9. doi: 10.1002/ajh.24999Serris A, Amoura Z, Canoui-Poitrine F, et al. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: a multicenter retrospective cohort study of 71 adults. Am J Hematol. 2018;93(3):424-9. doi: 10.1002/ajh.24999Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018;131(11):1172-82. doi: 10.1182/blood-2017-09-742353Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for immune thrombocytopenia: down but not out. Blood. 2018;131(11):1172-82. doi: 10.1182/blood-2017-09-742353You YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg. 2004; 240:286-92. doi: 10.1097/01.sla.0000133182.92780.9cYou YN, Tefferi A, Nagorney DM. Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus. Ann Surg. 2004; 240:286-92. doi: 10.1097/01.sla.0000133182.92780.9cArtim-Esen B, Cene E, Sahinkaya Y, et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol. 2014;41(7):1304-10. doi: 10.3899/jrheum.130984Artim-Esen B, Cene E, Sahinkaya Y, et al. Cluster analysis of autoantibodies in 852 patients with systemic lupus erythematosus from a single center. J Rheumatol. 2014;41(7):1304-10. doi: 10.3899/jrheum.130984Duarte-Garcia A, Barr E, Magder LS, et al. Predictors of incident proteinuria among patients with SLE. Lupus Sci Med. 2017;4(1): e000200. doi: 10.1136/lupus-2016-000200Duarte-Garcia A, Barr E, Magder LS, et al. Predictors of incident proteinuria among patients with SLE. Lupus Sci Med. 2017;4(1): e000200. doi: 10.1136/lupus-2016-000200Tang X, Huang Y, Deng W, et al. Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: a retrospective review of 917 patients in South China. Medicine (Baltimore). 2010;89(1):62-7. doi: 10.1097/MD.0b013e3181cb449cTang X, Huang Y, Deng W, et al. Clinical and serologic correlations and autoantibody clusters in systemic lupus erythematosus: a retrospective review of 917 patients in South China. Medicine (Baltimore). 2010;89(1):62-7. doi: 10.1097/MD.0b013e3181cb449cHoussiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus nephritis trial, a randomized trial of low-dose versus highdose intravenous cyclophosphamide. Arthritis Rheum. 2002; 46:2121-31. doi: 10.1002/art.10461Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus nephritis trial, a randomized trial of low-dose versus highdose intravenous cyclophosphamide. Arthritis Rheum. 2002; 46:2121-31. doi: 10.1002/art.10461Rijnink EC, Teng YKO, Wilhelmus S, et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734-43. doi: 10.2215/CJN.10601016Rijnink EC, Teng YKO, Wilhelmus S, et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734-43. doi: 10.2215/CJN.10601016Walsh M, Solomons N, Lisk L, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva lupus management study. Am J Kidney Dis. 2013;61(5):710-5. doi: 10.1053/j.ajkd.2012.11.042Walsh M, Solomons N, Lisk L, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva lupus management study. Am J Kidney Dis. 2013;61(5):710-5. doi: 10.1053/j.ajkd.2012.11.042Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from longterm followup of patients in the Euro-Lupus nephritis trial. Arthritis Rheum. 2004; 50:3934-40. doi: 10.1002/art.20666Houssiau FA, Vasconcelos C, D'Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from longterm followup of patients in the Euro-Lupus nephritis trial. Arthritis Rheum. 2004; 50:3934-40. doi: 10.1002/art.20666Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-95. doi: 10.1056/NEJMoa1014460Dooley MA, Jayne D, Ginzler EM, et al. Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med. 2011;365(20):1886-95. doi: 10.1056/NEJMoa1014460Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the maintain nephritis trial. Ann Rheum Dis. 2010;69(12):2083-9. doi: 10.1136/ard.2010.131995Houssiau FA, D'Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the maintain nephritis trial. Ann Rheum Dis. 2010;69(12):2083-9. doi: 10.1136/ard.2010.131995Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-44. doi: 10.1053/j.ajkd.2010.08.036Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: a multicenter randomized clinical trial. Am J Kidney Dis. 2011;57(2):235-44. doi: 10.1053/j.ajkd.2010.08.036Lee YH, Lee HS, Choi SJ, et al. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20(6):636-40. doi: 10.1177/0961203310389486Lee YH, Lee HS, Choi SJ, et al. Efficacy and safety of tacrolimus therapy for lupus nephritis: a systematic review of clinical trials. Lupus. 2011;20(6):636-40. doi: 10.1177/0961203310389486Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled doubleblind multicenter study. Mod Rheumatol. 2009;19(6):606-15. doi: 10.1007/s10165-009-0218-5Miyasaka N, Kawai S, Hashimoto H. Efficacy and safety of tacrolimus for lupus nephritis: a placebo-controlled doubleblind multicenter study. Mod Rheumatol. 2009;19(6):606-15. doi: 10.1007/s10165-009-0218-5Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26. doi: 10.7326/M14-1030Liu Z, Zhang H, Liu Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162(1):18-26. doi: 10.7326/M14-1030Szeto C-C, Kwan BC-H, Lai FM-M, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008;47(11):1678-81. doi: 10.1093/rheumatology/ken335Szeto C-C, Kwan BC-H, Lai FM-M, et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford). 2008;47(11):1678-81. doi: 10.1093/rheumatology/ken335Uchino A, Tsukamoto H, Nakashima H, et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010;28(1):6-12.Uchino A, Tsukamoto H, Nakashima H, et al. Tacrolimus is effective for lupus nephritis patients with persistent proteinuria. Clin Exp Rheumatol. 2010;28(1):6-12.Панафидина ТА, Попкова ТВ. Общие принципы лечения волчаночного нефрита с профилактикой сердечно-сосудистых осложнений. Современная ревматология. 2018;12(4):4-8 doi: 10.14412/1996-7012-2018-4-4-8Panafidina TA, Popkova TV. General principles in the treatment of lupus nephritis with the prevention of cardiovascular events.Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2018;12(4):4-8 (In Russ.). doi: 10.14412/1996-7012-2018-4-4-8Arnaud L, Mathian A, Ruffatti A, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;13(3):281-91. doi: 10.1016/j.autrev.2013.10.014Arnaud L, Mathian A, Ruffatti A, et al. Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis. Autoimmun Rev. 2014;13(3):281-91. doi: 10.1016/j.autrev.2013.10.014Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529-39. doi: 10.1056/NEJMoa1804988Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379:1529-39. doi: 10.1056/NEJMoa1804988Ridker PM. Should aspirin be used for primary prevention in the Post-Statin era? N Engl J Med. 2018;379(16):1572-4. doi: 10.1056/NEJMe1812000Ridker PM. Should aspirin be used for primary prevention in the Post-Statin era? N Engl J Med. 2018;379(16):1572-4. doi: 10.1056/NEJMe1812000Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010; 8:237-42. doi: 10.1111/j.1538-7836.2009. 03674.xPengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010; 8:237-42. doi: 10.1111/j.1538-7836.2009. 03674.xPengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018; 132:1365-71. doi: 10.1182/blood-2018-04-848333Pengo V, Denas G, Zoppellaro G, et al. Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome. Blood. 2018; 132:1365-71. doi: 10.1182/blood-2018-04-848333Singh JA, Hossain A, Kotb A, et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137. doi: 10.1186/s12916-016-0673-8Singh JA, Hossain A, Kotb A, et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis. BMC Med. 2016;14(1):137. doi: 10.1186/s12916-016-0673-8Rua-Figueroa I, Lopez-Longo J, Galindo-Izquierdo M, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2017;47(1):38-45. doi: 10.1016/j.semarthrit.2017.01.010Rua-Figueroa I, Lopez-Longo J, Galindo-Izquierdo M, et al. Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2017;47(1):38-45. doi: 10.1016/j.semarthrit.2017.01.010Furer V, Rondaan C, Elkayam O, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019 Aug 14. doi: 10.1136/annrheumdis-2019-215882Furer V, Rondaan C, Elkayam O, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2019 Aug 14. doi: 10.1136/annrheumdis-2019-215882Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third International consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315:762-74. doi: 10.1001/jama.2016.0288Seymour CW, Liu VX, Iwashyna TJ, et al. Assessment of clinical criteria for sepsis: for the third International consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016; 315:762-74. doi: 10.1001/jama.2016.0288Ballocca F, D'Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Nov;22(11):1435-41. doi: 10.1177/2047487314546826Ballocca F, D'Ascenzo F, Moretti C, et al. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015 Nov;22(11):1435-41. doi: 10.1177/2047487314546826Wu GC, Leng RX, Lu Q, et al. Subclinical atherosclerosis in patients with inflammatory bowel diseases: A systematic review and meta-analysis. Angiology. 2017 May;68(5):447-61. doi: 10.1177/0003319716652031Wu GC, Leng RX, Lu Q, et al. Subclinical atherosclerosis in patients with inflammatory bowel diseases: A systematic review and meta-analysis. Angiology. 2017 May;68(5):447-61. doi: 10.1177/0003319716652031Gustafsson JT, Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity. 2014 Mar;47(2):67-76. doi: 10.3109/08916934.2013.856005Gustafsson JT, Svenungsson E. Definitions of and contributions to cardiovascular disease in systemic lupus erythematosus. Autoimmunity. 2014 Mar;47(2):67-76. doi: 10.3109/08916934.2013.856005Udachkina HV, Novikova DS, Popkova TV, et al. Dynamic of changes in coronary artery calcification in early rheumatoid arthritis patients over 18 months. Rheumatol Int. 2018 Jul;38(7):1217-24. doi: 10.1007/s00296-018-4045-xUdachkina HV, Novikova DS, Popkova TV, et al. Dynamic of changes in coronary artery calcification in early rheumatoid arthritis patients over 18 months. Rheumatol Int. 2018 Jul;38(7):1217-24. doi: 10.1007/s00296-018-4045-xUdachkina HV, Novikova DS, Popkova TV, et al. Calcification of coronary arteries in early rheumatoid arthritis prior to antirheumatic therapy. Rheumatol Int. 2018 Feb;38(2):211-7. doi: 10.1007/s00296-017-3860-9Udachkina HV, Novikova DS, Popkova TV, et al. Calcification of coronary arteries in early rheumatoid arthritis prior to antirheumatic therapy. Rheumatol Int. 2018 Feb;38(2):211-7. doi: 10.1007/s00296-017-3860-9Fasano S, Pierro L, Pantano I, et al. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol. 2017 Jul;44(7):1032-8. doi: 10.3899/jrheum.161351Fasano S, Pierro L, Pantano I, et al. Longterm hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol. 2017 Jul;44(7):1032-8. doi: 10.3899/jrheum.161351Iudici M, Fasano S, Gabriele Falcone L, et al. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology (Oxford). 2016 Sep;55(9):1623-30. doi: 10.1093/rheumatology/kew231Iudici M, Fasano S, Gabriele Falcone L, et al. Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: a long-term retrospective cohort study. Rheumatology (Oxford). 2016 Sep;55(9):1623-30. doi: 10.1093/rheumatology/kew231Gaziano JM, Brotons C, Coppolecchia R, Cricelli C. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-46. doi: 10.1016/S0140-6736(18)31924-XGaziano JM, Brotons C, Coppolecchia R, Cricelli C. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036-46. doi: 10.1016/S0140-6736(18)31924-XPetri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis. 2011 May;70(5):760-5. doi: 10.1136/ard.2010.136762Petri MA, Kiani AN, Post W, et al. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis. 2011 May;70(5):760-5. doi: 10.1136/ard.2010.136762Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012 Jan;64(1):285-96. doi: 10.1002/art.30645Schanberg LE, Sandborg C, Barnhart HX, et al. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum. 2012 Jan;64(1):285-96. doi: 10.1002/art.30645Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81. doi: 10.1093/eurheartj/ehw106Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016 Aug 1;37(29):2315-81. doi: 10.1093/eurheartj/ehw106Панафидина ТА, Попкова ТВ, Алекберова ЗС и др. Значение факторов риска и С-реактивного белка в развитии атеросклероза у женщин с системной красной волчанкой. Клиническая медицина. 2006;84(10):49-54Panafidina TA, Popkova TV, Alekberova ZS, et al. The importance of risk factors and C-reactive protein in the development of atherosclerosis in women with systemic lupus erythematosus. Klinicheskaya Meditsina. 2006;84(10):49-54 (In Russ.).Попкова ТВ, Алекберова ЗС, Александрова ЕН и др. Факторы риска кардиоваскулярных нарушений и атеросклероза при системной красной волчанке. Научно-практическая ревматология. 2004;42(4):10-4 doi: 10.14412/1995-4484-2004-795Popkova TV, Alekberova ZS, Aleksandrova EN, et al. Cardiovascular disturbances and atherosclerosis risk fасtore in systemic lupus erythematosus. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2004;42(4):10-4 (In Russ.). doi: 10.14412/1995-4484-2004-795Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003. doi: 10.1016/S0195-668X (03)00114-3Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24:987-1003. doi: 10.1016/S0195-668X (03)00114-3

The authors declare that there are no conflicts of interest present.